Business Standard

Monday, January 06, 2025 | 06:11 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Dr Reddy's slips 7% following 8 USFDA observations for Duvvada plant

The stock slipped 7% to Rs 2,425 on the BSE after the pharmaceutical company said US health regulator issued eight observations after inspecting its formulations plant at Duvvada, Visakhapatnam.

Image via Shutterstock
Premium

<a href="http://www.shutterstock.com/pic-141058420.html" target="_blank">Image</a> via Shutterstock

SI Reporter Mumbai
Shares of Dr. Reddy’s Laboratories have slipped 7% to Rs 2,425 per share on the BSE in early morning trade after the pharmaceutical company said that the US health regulator issued eight observations after inspecting its formulations plant at Duvvada, Visakhapatnam.

"The audit of our formulations manufacturing facility at Duvvada, Visakhapatnam, by the US Food and Drug Administration (USFDA), has been completed today. We have been issued a Form 483 with 8 observations, which we are addressing," the company said in a filing.

As per the USFDA, Form 483 is issued to a firm's management at the conclusion

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in